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Abstract
Chronic pain has been associated with impaired cognitive function. We examined cognitive performance in patients with
severe chronic pancreatitis pain. We explored the following factors for their contribution to observed cognitive deficits: pain
duration, comorbidity (depression, sleep disturbance), use of opioids, and premorbid alcohol abuse. The cognitive profiles
of 16 patients with severe pain due to chronic pancreatitis were determined using an extensive neuropsychological test
battery. Data from three cognitive domains (psychomotor performance, memory, executive functions) were compared to
data from healthy controls matched for age, gender and education. Multivariate multilevel analysis of the data showed
decreased test scores in patients with chronic pancreatitis pain in different cognitive domains. Psychomotor performance
and executive functions showed the most prominent decline. Interestingly, pain duration appeared to be the strongest
predictor for observed cognitive decline. Depressive symptoms, sleep disturbance, opioid use and history of alcohol abuse
provided additional explanations for the observed cognitive decline in some of the tests, but to a lesser extent than pain
duration. The negative effect of pain duration on cognitive performance is compatible with the theory of
neurodegenerative properties of chronic pain. Therefore, early and effective therapeutic interventions might reduce or
prevent decline in cognitive performance, thereby improving outcomes and quality of life in these patients.
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Introduction
Chronic pancreatitis is a serious medical disease characterized
by inflammation of the pancreas resulting in progressive and
irreversible morphological changes and often end-stage exocrine/
endocrine failure [1]. Alcohol abuse is the most common etiology
in chronic pancreatitis, preceding the disease in 55%–80% of
chronic pancreatitis patients in industrialized nations [2]. Severe
chronic abdominal pain is the major presenting complaint present
in 80%–90% of patients during the course of the disease [3,4].
Pain can be considered the most important factor causing a
substantial loss of quality of life [5]. The intense relapsing or
persistent pain in chronic pancreatitis leads to recurrent
hospitalizations, multiple medical interventions, opioid addiction
[6,7] and is associated with major socio-economic problems [8].
The pain in chronic pancreatitis is still not completely understood,
but does involve peripheral nociceptive, peripheral neuropathic
and central neuroplastic mechanisms [9].
It is now well accepted that neuroplasticity, i.e. altered central
pain processing, plays an important role in the development of
chronic pain [10]. Once pain has become chronic, as in chronic
pancreatitis, it is difficult to treat satisfactorily [3]. Thus surgical
treatments aiming to interrupt nociceptive input from the
pancreas, e.g. celiac plexus blockade, pancreatic denervation, or
total pancreatectomy, fail to relieve pain in a substantial
proportion of patients with chronic pancreatitis [11]. In general,
long-term quality of life remains poor after surgery in patients with
chronic pancreatitis [12]. The accompanying invalidity, reduced
ability to work, induced sleep disturbances, increased anxiety and
depressive symptoms [13,14], make chronic pancreatitis pain an
unsolved healthcare problem in society.
Many patients suffering from chronic pain report cognitive
complaints. There is substantial evidence that chronic pain can
impair cognitive abilities [15,16,17,18,19,20,21,22,23,24].
However, most of these studies included patients with
unspecified pain and pain syndromes of varying etiologies
[22,25]. Moreover, explanations for the observed cognitive decline
remain scarce. Possible explanations might be related to the
observed chemical and structural changes in the brain of patients
suffering from chronic pain [26,27,28]. Indeed, MRI research has
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shown that in patients suffering chronic pain, gray matter density
is decreased, especially in the prefrontal cortex and the thalamus
[29,30,31,32]. Apkarian and colleagues reported that chronic pain
patients were impaired on an emotional decision task, a test that
has been directly linked to functional properties of the frontal lobe
[33]. The authors explained their findings in terms of loss of gray
matter in the frontal lobe of chronic pain patients [33]. To our
knowledge, this was the first study directly linking neurodegener-
ation, chronic pain and a specific cognitive deficit.
In acute and chronic neurodegenerative diseases, neuronal cell
death is also an important factor underlying the observed decline
in cognitive functions [34]. In view of shared disease mechanisms
(e.g. neuronal necrosis), it has been suggested that chronic pain
should also be considered a neurodegenerative disorder [26].
Apart from severe pain, many chronic pancreatitis patients
report also other factors that have been associated with a decrease
in cognitive functions, such as depressive symptoms [35,36,37],
sleep disturbances [38], use of opioid medication [39], and a
history of alcohol abuse [40].
The objectives of this study were 3-fold. Firstly, we wanted to
examine whether chronic pancreatitis pain is associated with
cognitive decline. A second objective was to examine whether
documented cognitive deficits are related to pain duration,
supporting the hypothesis that chronic pain is a progressive
neurodegenerative disorder. Thirdly, our aim was to examine to
what extent other individual factors, e.g. depressive symptoms,
sleep disturbance, opioid medication and a history of alcohol
abuse, contribute to the cognitive decline of patients with chronic
pancreatitis. To this end, the neuropsychological profile of chronic
pancreatitis patients was documented by means of a complete
neuropsychological test battery and compared with the neuropsy-
chological profile of healthy controls matched for age, gender, and
education.
Methods
Study design
Over a ten-month period, sixteen patients with confirmed
chronic pancreatitis and associated chronic pain were referred to
the Brainclinics Research Institute, Nijmegen, the Netherlands, for
standardized assessment of their cognitive abilities. The diagnosis
of pancreatitis was based on a standard battery of history,
laboratory tests and radiological findings. Patients were ambulant
and randomly selected from the outpatient clinic. Patients with
persistent alcohol use were excluded from the study. The control
group consisted of 16 healthy volunteers who were matched to the
chronic patient group according to age, gender, and years of
education. For all participants, the standardized neuropsycholog-
ical assessment protocol of the Brain Resource International
Database was used [41]. For a description of demographic
variables of the healthy volunteers and the chronic pancreatitis
patients, see Table 1 upper panel.
For the healthy volunteers, medical ethical approval to collect
the data was obtained (Committee on Research involving Human
Subjects, Region Arnhem-Nijmegen nr. 2002/008). The patients
were all referred by their physician in charge for neuropsycho-
logical testing, as part of their medical follow up. Written informed
consent to use the data for scientific purpose was signed by all
subjects, both healthy volunteers and patients.
Data collection
Cognitive abilities were assessed by means of the Integneuro test
battery using an automated touch screen tool [41]. The
participants were instructed to refrain from smoking and drinking
caffeine 2 hours before the study. They were seated in front of a
touch screen computer (NEC MultiSync LCD 1530 V) in a sound
attenuated room. Task instructions and materials were pre-
recorded and delivered in a standardized way via headphones
and using the visual display on the touch screen computer. The
Integneuro test battery consisted of 13 tests, which covered three
clusters of cognitive domains, namely psychomotor performance,
memory, and executive functions. Some tests consisted of two or
more subtests. For a description of the tests used, see [41] and
Appendix S1. The total test battery took approximately 50 min-
utes to complete.
Pain duration
The period (in years) that the chronic pancreatitis patients were
under medical control for pain treatment was taken as measure of
pain duration. Matched controls were free of chronic pain and
scored 0 on this variable.
Additional variables
Apart from group (chronic pancreatitis patients versus matched
healthy volunteers) and pain duration, four covariates were
included in this study; depressive mood, sleep disturbances, opioid
use, and a history of alcohol abuse.
Table 1. Demographic and individual variables of the participants.
Demographic variables of the participants Healthy controls Patients
Number of participants (n) 16 16
Age (years) (mean 6 SD) 48.0611.3 49.5611.9
Male/Female (n/n) 10/6 10/6
Years of education (mean 6 SD) 11.962.9 11.863.1
Individual variables of the participants
Pain duration (years) (mean 6 SD) 0 6.1263.01
Depression (DASS-21) (mean 6 SD) 1.7562.38 5.2764.78
Sleeping disturbance (yes/no) 7/9 6/10
Opioid medication (yes/no) 0/16 8/8
History of alcohol abuse (yes/no) 0/16 8/8
doi:10.1371/journal.pone.0023363.t001
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In both patients and healthy volunteers, depressive mood was
assessed by the short-form version of the Depression Anxiety Stress
Scales (DASS-21) [42]. The DASS-21 is comprised of a 21-item
questionnaire referring to the severity/frequency of negative
emotional symptoms experienced ‘‘over the past week’’ with each
item rated on a 4-point scale. The score for depression was
calculated by summing the scores for the relevant items.
Information about sleep disturbance and opioid medication was
obtained through a screening questionnaire leading to either the
presence of sleep disturbances or not in both the patients and
healthy volunteers. Information about a history of alcohol abuse in
the past and or the use of opioid medication was extracted from
the medical files of the patients (Table 1 lower panel). Sleep
disturbance, use of opioid medication, and a history of alcohol
abuse were scored in a dichotomous way (yes/no).
Data and statistical analysis
The data of the current study were considered to be
hierarchical, meaning there were measurements (level 1) within
participants (level 2) and the test scores from these measurements
were clustered in three different cognitive domains: psychomotor
performance, memory, and executive functions. From this we
expected dependency within the data. Therefore, a multivariate
multilevel analysis was applied for the current data [43,44] The
use of a multilevel approach was further supported by its
permitting the retention of participants that had missing data
amongst the dependent variables (see Table 2).
A multivariate multilevel analysis with fixed occasion models
was used. The models were set up using a one-by-one backward
removal of non-significant fixed effects (the criterion was 1.65 for a
Wald test, one sided 0.05 significance). Next, one-by-one non-
significant covariances were removed using a deviance test. The
last step consisted of the removal (once more) of non-significant
fixed effects. We followed this procedure to ensure we did not
overlook suppression effects and that the covariance matrix was,
initially, as free as possible. For the analysis the package MLwiN
(version 1.10.000.6) was used (www.bristol.ac.uk/cmm/software/
mlwin/). For details of the analysis see [45,46].
For the clusters psychomotor performance, memory, and
executive functions, four models were evaluated:
Model 0: this model was used for reference.
Model 1: group.
Model 2: pain duration.
Model 3: group and pain duration.
Model 4: group, pain duration and consecutive covariates
(depression, sleep disturbances, use of opioid medication, and a
history of alcohol abuse).
These models were not nested, thus comparison of the models
using the standard deviance test was not appropriate. We used the
Akaike’s Information Criteria corrected for small samples (AICc)
Table 2. Raw scores of the participants of all the variables.
Cluster Test nr Variable measured Healthy controls Patients
Mean (SE) N Mean (SE) N
Psychomotor 1 Tapping freq. (dominant) (#) 164 (9) 16 133 (13) 11
Tapping freq. (non-dominant) (#) 154 (7) 16 130 (11) 11
Tapping variability (dominant) (ms) 21.1 (3.7) 16 77.3 (22.9) 11
Tapping variability (non-dominant) (ms) 29.1 (4.6) 16 67.6 (22.5) 11
2 Target detection (ms) 321 (12) 13 375 (24) 13
3 Choice Reaction Time (ms) 688 (19) 16 816 (40) 16
4 Working Memory Reaction Time (ms) 503 (36) 13 604 (40) 15
Memory 5 Verbal word Learning trials (#) 7.5 (0.3) 16 6.9 (0.4) 16
Verbal word Learning trials (slope) 1.0 (0.1) 16 1.0 (0.2) 16
Verbal word Delayed recall (mean) 6.1 (0.6) 16 5.7 (0.6) 16
Verbal word Recognition (sensitivity) 0.7 (0.3) 16 0.7 (0.4) 16
6 Maze A (s) 279 (36) 16 353 (56) 14
Maze B (s) 242 (34) 16 305 (48) 14
Digit span forward task 5.7 (0.3) 16 5 (0.3) 16
7 Digit span backward task 3.7 (0.3) 16 3.5 (0.4) 15
8 Visual Span 6.4 (0.7) 15 6.4 (0.7) 13
Executive 9 Switching of Attention 1 (s) 22.3 (1.3) 16 30.8 (3.4) 16
10 Switching of Attention 2 (s) 56.3 (5.7) 16 71.9 (7.0) 16
Switching of Attention 2 (errors) 0.9 (0.3) 16 3.4 (1.1) 14
11 Verbal Interference (correct) 9.4 (0.9) 16 6.0 (0.9) 16
Verbal Interference (errors) 1.2 (0.3) 16 1.8 (0.3) 16
12 Intrusions 0.1 (0.1) 16 0.4 (0.1) 16
13 Go-NoGo (ms) 311 (15) 13 350 (21) 12
Mean and standard error (SE) with number of participants (N) of the unstandardized cognitive tests scores in the psychomotor -, memory - and executive functioning
cluster.
doi:10.1371/journal.pone.0023363.t002
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to evaluate the multiple regression models and select the ‘‘best’’
model for cognitive functions for each cluster at two levels (see
Appendix S2).
For the multivariate multilevel analysis the test score variables
for the clusters psychomotor performance, memory, and executive
functions, were standardized (range between 22 and 2, mean
zero). The predictor ‘group’ was a dichotomous variable (patients
versus healthy controls) and the predictor ‘pain duration’ was a
continuous variable with standardized values within the patients
group (where the value for the control group is arbitrary and
chosen to be 0 as it does not vary within that group). All covariates
were dichotomous variables, except for the depression score,
which was continuous and these scores were standardized in the
multilevel analysis (range between 22 and 2, mean zero).
Effects (E) on the test scores of the neuropsychological tests were
calculated and in order to compare the effects, effect sizes (ES) for
the continuous and dichotomous variables were calculated (see
Appendix S3).
For a comprehensive illustration of the calculation and
interpretation of estimated effects and effect sizes of the predictors
‘group’ and ‘pain duration’ see Appendix S4.
Results
Demography
The study sample consisted of 16 patients with chronic
pancreatitis pain and 16 healthy controls. Patients and healthy
controls were matched according to age, gender, and years of
education (Table 1). Mean duration of chronic pancreatitis pain
was 6 years, 8 patients had a history of alcohol abuse and 8
patients used opioid medication to relieve their pain (Table 1).
Psychomotor performance
For the cluster psychomotor performance, model 2 with the
predictor ‘pain duration’ (period of pain in years) had a lower
AICc value (366.8) compared to the AICc of model 1 (376.2)
including the predictor ‘group’ (patient or healthy control)
(Table 3). Therefore, ‘pain duration’ was a better predictor than
the predictor ‘group’ for the observed test scores on psychomotor
performance. In addition, model 4 had the lowest AICc value
(325.9). This model, including the predictors ‘group’ and ‘pain
duration’ together with consecutive covariates, gave the best
explanation (i.e. fit) for the variance in the observed test scores for
psychomotor performance (Table 3). Table 4 shows the significant
effects of ‘group’ and ‘pain duration’ for the cluster psychomotor
performance with model 1, 2, 3 and 4.
The effects of ‘group’ were significant for all seven tests when
‘pain duration’ and covariates were included (i.e. model 4),
meaning that chronic pain patients performed worse on all tasks
within the psychomotor cluster compared to the healthy controls
(Table 2, Table 4 upper panel). Vice versa, the effect of ‘pain
duration’ remained a significant predictor, when ‘group’ and
covariates were included (model 4, Table 4 lower panel). In more
detail, a comparison between the predictor ‘group’ and the
predictor ‘pain duration’ on e.g. the ‘Tapping frequency’ tasks
regarding effects showed that the effect sizes of ‘pain duration’
with significant estimated effects (20.62, dominant hand) and
(20.47, non-dominant hand) were higher than the effect sizes of
‘group’ with significant estimated effects (20.73 and 20.71
respectively) (Table 4). Thus on the ‘Tapping frequency’ tasks
pain patients tapped significantly more slowly compared to healthy
controls. In addition, tapping frequency was significantly further
decreased in patients with long pain duration compared to patients
with short pain durations. Also, the effect sizes for ‘pain duration’
with significant estimated effects (20.84) and (20.75) on the
‘Tapping variability’ of the dominant and non-dominant hand
were higher than the effect sizes for ‘group’ with significant
estimated effects (21.13) and (21.49). Patients showed signifi-
cantly more variability between tapping compared to the healthy
controls on this task and this variability significantly further
increased with longer pain durations (Table 4). Similarly, in the
‘Target detection’ task the effect size of ‘pain duration’ with a
significant estimated effect (20.55) was stronger than the effect size
for ‘group’ with significant estimated effect (21.85) on the reaction
times in this task. Thus, patients showed an increase in reaction
time compared to the healthy controls and long pain durations
were accompanied by prolonged reaction times compared to short
pain durations in this ‘Target detection task’.
With respect to the domain of psychomotor performance which
comprised seven tests, the covariate depression appeared to hold
additional explanatory effects with respect to two tests: the
‘‘Variability’ in taps of the non-dominant hand and performance
on the ‘Choice Reaction Time’ test. Similarly, a presence of sleep
disturbance holds additional explanatory effects for two tests:
‘Tapping’ with the dominant hand and with the non-dominant
hand. Finally, the use of opioid medication also holds additional
explanatory effects for two tests: ‘Variability’ in taps of the
dominant and the non-dominant hand. A history of alcohol abuse
Table 3. Statistical outcomes of the multivariate analysis.
Model 0 reference Model 1 group Model2 duration
Model 3 group
and duration
Model 4 group and
duration and
covariates
Psychomotor Fit 328.0 320.7 311.2 300.1 193.4
(cases, parameters) (184,21) (184, 24) (184, 24) (184, 28) (178, 48)
AICc 375.7 376.2 366.8 366.6 325.9
Memory Fit 507.1 504.4 480.9 480.9 439.9
(cases, parameters) (283, 35) (283, 35) (273, 39) (273, 39) (270, 49)
AICc 587.3 584.6 572.3 572.3 560.2
Executive Fit 444.9 438.0 425.7 412.6 362.2
(cases, parameters) (191, 22) (191, 25) (191, 24) (191, 30) (185, 38)
AICc 494.9 495.9 480.9 484.2 458.5
Fits (with corresponding cases and parameters) and AICc values for the clusters psychomotor -, memory - and executive functions.
doi:10.1371/journal.pone.0023363.t003
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Table 4. Significant effects of the multivariate analysis.
Cluster Test nr Variable measured
Model 1 group
only
Model 2 duration
only
Model 3 group
and duration
Model 4 group
and duration
and covariates
Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE)covariates
Predictor Group
Psychomotor 1 Tapping freq.(dominant) 20.73 (0.27)2
Tapping freq.(non-dominant) 20.71 (0.28)2,4
Tapping variability (dominant) 20.43 (0.14) 21.13 (0.26)3,4
Tapping variability (non-dominant) 21.49 (0.29)1,3,4
2 Target detection (time) 20.49 (0.26) 20.44 (0.26) 21.85 (0.34)4
3 Choice Reaction Time 20.44 (0.20) 20.39 (0.20) 20.51 (0.28)1,4
4 Working Memory Reaction Time 20.46 (0.25) 20.48 (0.26) 21.39 (0.38)4
Memory 5 Verbal word Learning trials (#) 3,4
Verbal word Learning trials (slope)
Verbal word Delayed recall 0.49 (0.15)4
Verbal word Recognition 20.67 (0.31)3
6 Maze A 0.55 (0.27)1,3,4
Maze B 20.59 (0.28)1,4
Digit span forward task
7 Digit span backward task
8 Visual Span 0.29 (0.16) 2
Executive 9 Switching of Attention 1 20.80 (0.22)
10 Switching of Attention 2
Switching of Attention 2 (errors) 0.69 (0.22)
11 Verbal Interference (correct) 20.60 (0.21) 21.06 (0.14)2,3
Verbal Interference (errors)
12 Intrusions 0.64 (0.25) 0.58 (0.27)3
13 Go-NoGo 0.63 (0.36) 0.79 (0.33) 1.63 (0.42)1
Predictor Pain duration
Psychomotor 1 Tapping freq.(dominant) 20.55 (0.20) 20.21 (0.06) 20.62 (0.19)2
Tapping freq.(non dominant) 20.39 (0.22) 20.47 (0.21)2,4
Tapping variability (dominant) 20.69 (0.20) 20.40 (0.10) 20.84 (0.16)3,4
Tapping variability (non dominant) 20.37 (0.22) 20.75 (0.18)1,3,4
2 Target detection (time) 20.41 (0.20) 20.34 (0.19) 20.55 (0.17)4
3 Choice Reaction Time
4 Working Memory Reaction Time
Memory 5 Verbal word Learning trials (#) 20.45 (0.24) 20.45 (0.24) 3
Verbal word Learning trials (slope)
Verbal word Delayed recall 20.46 (0.22) 20.46 (0.22)
Verbal word Recognition 3
6 Maze A 20.49 (0.24) 20.49 (0.24) 20.05 (0.01)1
Maze B 20.45 (0.24) 20.45 (0.24)
Digit Forward task 20.51 (0.24) 20.51 (0.24) 20.29 (0.14)
7 Digit Backward task
8 Visual Span 2
Executive 9 Switching of attention 1 20.62 (0.15) 20.64 (0.15) 20.49 (0.10)2,3
10 Switching of attention 2 20.35 (0.15) 20.34 (0.15)
Switching of attention 2 (errors) 0.78 (0.18) 0.81 (0.17) 0.57 (0.14)1,4
11 Verbal Interference (correct)
Verbal Interference (errors)
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appeared to have additional explanatory effects with respect to the
six tests: ‘Tapping’ with the non dominant hand, ‘Variability’ in
taps of both the dominant and the non-dominant hand, ‘Choice
Reaction Time’ test, ‘Target Detection’ test, and ‘Working
Memory’ test. Alcohol abuse is therefore the covariate with the
greatest impact.
Memory
In the cluster memory, the ranking of the AICc values of the 4
different models showed that model 2 with the predictor ‘pain
duration’ (AICc 572.3) was the better statistical model for
explaining memory compared to model 1 with the predictor
‘group’ (AICc 584.6). Thus the predictor ‘pain duration’ was a
better predictor than the predictor ‘group’ (chronic pancreatitis
patient or healthy control) with respect to memory. However, this
advantage disappeared when covariates were added in the model
(Table 4). Model 4 had the lowest AICc value (560.2), so the
predictors ‘group’ and ‘pain duration’ and consecutive covariates
together best explained the observed test scores for memory
performance (Table 3).
The estimated effects of ‘group’ in model 4 were significant for
both parts of the ‘Maze learning’ tasks (0.55) and (20.59),
‘Delayed recall’ of the verbal word learning task (0.49) and
‘Recognition’ of the verbal word learning task (20.67) tests. Thus
pain patients scored less accurately on these tasks compared to
healthy controls (Table 2, Table 4 upper panel). In the test ‘Digits
Forward’ task, long pain duration gave significantly decreased
scores compared to short pain duration, with an estimated effect of
(20.29) for pain duration.
The cluster memory compromised nine tests. Depression
appeared to be of relevance by having additional explanatory
effects with respect to two tests (‘Maze learning’ A and B). In
addition sleep disturbance had additional explanatory effects in
one test: the ‘Visual span’ test. The use of opioid medication had
additional explanatory effects with respect to three tests: ‘Maze
learning A’, verbal word learning and recognition of verbal word
learning. A history of alcohol abuse had additional explanatory
effects in four tests within the cluster memory: maze learning A
and B, verbal word learning and the delayed recall of verbal word
learning.
Executive functions
In the cluster executive functions, the model with ‘pain
duration’ (AICc 480.9) better explained the test scores of executive
functions than the model with ‘group’ (AIC 495.9). Multilevel
analysis showed that duration of pain remained of importance
when the covariates were included (model 4), according to the
estimated effects (Table 4). Again, model 4 had the lowest AICc
value (458.5) and therefore is the best fit for the test scores in the
cluster executive functions (Table 3).
The estimated effects of ‘group’ were significant with respect to
the tests ‘Switching of attention 1’ (20.80), correct responses on
the ‘Verbal interference’ test (21.06), ‘Intrusions’ on the verbal
word learning task (0.58), and reaction times to the ‘Go-NoGo’
task (1.63), meaning that patients showed a significant decline in
executive functions compared to the healthy controls (Table 2,
Table 4 upper panel). The predictor ‘pain duration’ had
significant estimated effects for the speed in ‘Switching of attention
1’ test (20.49) and errors on the ‘Switching of attention 2’ test
(0.57). The effect size of ‘pain duration’ with significant estimated
effect (20.49) is higher compared to the effect size of group with
significant estimated effect (20.80) for the ‘Speed in switching of
attention 1’ test. Depression had relevant explanatory effects next
to ‘pain duration’ and ‘group’ with respect to two executive
function tests: the number of errors in the ‘Switching of attention
2’ and the reaction times in the ‘Go-NoGo’ task. In addition, sleep
disturbance had explanatory effects with respect to two tests: the
speed in ‘Switching of attention 2’ (time) and on correct responses
in the ‘Verbal interference’ test. The use of opioid medication had
explanatory effects in three tests: correct responses on the ‘Verbal
interference’ test, ‘Intrusions’ and speed of ‘Switching of attention
1’. Finally, a history of alcohol abuse only had additional effects on
the errors on the ‘Switching of attention 2 test’.
In summary, for each cognitive cluster, the predictor ‘pain
duration’ (model 2) gave a better explanation for the variance in
cognitive performance (i.e. had a lower AICc value) than the
predictor ‘group’ (model 1) did. However, variance in all three
cognitive domains could be best explained with model 4 which
included ‘group’ and ‘pain duration’ together with relevant
covariates of depression, sleep disturbance, opioid medication,
and a history of alcohol abuse. The mean performance of the
patients, in those nine tests that were significant deviant from
controls with respect of pain duration, was 73% of that of the
controls (SEM 3.4, n = 108 test values, Table 4 lower panel, model
4). The impact of the duration of the pain on this decline is
visualized in figure 1.
Discussion
The current study investigates whether chronic pancreatitis pain
is accompanied by a decline in cognitive performance, and
whether this decline could be related to neurodegenerative
Cluster Test nr Variable measured
Model 1 group
only
Model 2 duration
only
Model 3 group
and duration
Model 4 group
and duration
and covariates
Estimate (SE) Estimate (SE) Estimate (SE) Estimate (SE)covariates
12 Intrusions
13 Go-NoGo
Estimates and SE (standard error) from the multivariate multilevel analysis explaining test scores with predictors ‘group’ (upper panel) and ‘pain duration’ (lower panel).
(n= 32, 16 pain patients).
Shown are the significant effects of predictors ‘group’ and ‘pain duration’ on test scores in the psychomotor -, memory - and executive functioning clusters with
covariates of relevance.
All effects with p#0.05.
Covariates (1 = depression, 2 = sleep disturbance, 3 = opioid medication, and 4 = alcoholism).
doi:10.1371/journal.pone.0023363.t004
Table 4. Cont.
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properties of the chronic pain. Neuropsychological profiles of
patients suffering from chronic pancreatitis pain were compared to
those from healthy matched controls.
We found that patients with chronic pancreatitis pain
performed significantly worse on tests within all three cognitive
domains compared to matched healthy controls. Moreover, the
test scores could best be explained when pain duration was
included as a second predictor, additional to being a patient or
healthy control. Thus, longer pain durations were associated with
greater declines in cognitive performance of patients and ‘pain
duration’ resulted in larger effect sizes for predicting the test scores
on cognitive tasks than ‘group’ did.
Pain duration particularly affects functions in the cluster
psychomotor performance. Psychomotor performance strongly
relies on the intactness of the frontal lobes. Thus the psychomotor
slowing observed in the pancreatitis pain patients may be
attributable to alterations of motor- and premotor cortices as well
as midbrain structures regulating the general level of arousal (e.g.
the thalamus) [47].
The findings of the current study related to the domain of
psychomotor performance may further have been affected by all
four covariates investigated. These factors have all previously been
associated with a decrease in psychomotor speed [36,38,48,49]. In
the current study these four factors all offered some additional
explanation for the observed decrease in psychomotor perfor-
mance in the patients, but this appears less substantial than the
explanatory effect of pain duration.
Pancreatitis pain patients also showed impairments in executive
functions. Significant effects of pain duration were found on tasks
that highly depended on mental flexibility (i.e. switching of
attention task), self-monitoring abilities (i.e intrusions on word
learning) and withholding a response (i.e. verbal interference).
Executive functions represent a high, more abstract level of
processing, and are mainly supported by the prefrontal cortex
[50]. Interestingly, Apkarian et al., [29] observed a loss of cortical
grey matter in patients suffering from chronic pain, especially in
the frontal cortices and thalamus. In a subsequent study, a link
between decreased grey matter in the prefrontal lobe and a
reduced performance on an emotional decision-making task was
suggested [26,33]. The observed decline in psychomotor and
executive performance observed in our pancreatitis pain patients
might thus also be, at least partly, ascribed to a loss of grey matter
in the frontal cortices and thalamus.
Memory performance was the least affected cognitive function
in patients with chronic pancreatitis. Mild problems with memory
functioning have previously been related to depressive symptoms
[35,36,51]. Thus, a mild decline in memory might be related to
the increased depression scores found in the patients compared to
healthy controls. Although previous studies of patients with
chronic pain often have reported memory deficits [22,52], this
domain is only mildly affected within the current study.
Depression, sleep disturbance, use of opioids, and a history of
alcohol abuse, are all factors that have been associated with
decreased cognitive abilities. Therefore, in the current study these
factors were included in the models explaining the observed
variance in neuropsychological test data. Indeed, with respect to a
number of the tests, these factors did offer additional explanation
for the observed cognitive decline in pancreatitis patients. Of these
factors, a history of alcohol abuse appeared to be the most
prominent factor. However, the effect sizes of a history of alcohol
abuse were still modest in comparison with the effect sizes of
chronic pain and pain duration (data not shown). This limited
effect might be ascribed to the long duration of alcohol abstinence
at time of testing in our patients, i.e. at least one year. Indeed,
significant recovery has been found within one year of abstinence
in most cognitive domains [53,54,55,56]. Fein et al. examined
cognitive performance in long-term abstinent middle-aged alco-
holics and found that abstinent alcoholics performed similarly to
controls in all areas of cognitive performance, except for a minor
deficit in spatial processing [55].
In this study a homogenous group of patients was recruited, all
having a confirmed diagnosis of pancreatitis. Despite the patients
being homogenous in the cause of the pain, it is still difficult to
ascribe the observed cognitive deficits to just one underlying cause.
This difficulty is not only due to the variation in the duration of
their pain disease but also due to comorbidity with depression,
sleep disturbances, the high prevalence of a history of alcohol
abuse and a current use of opioid medication. However, by
applying multivariate multilevel analyses we were able to entangle
at least partially the differential influences of these contributing
factors.
The uniqueness of this study is that it is the first study to
formally assess the cognitive performance of chronic pancreatitis
pain patients. Previous studies in this field have focused on other
chronic pain patients e.g. low back pain [57] and fibromyalgia
[23,25,58], or mixed pain conditions in patients with chronic non-
malignant pain [22,59]. The similar findings of a decline in
cognitive performance in these previous studies and those in the
present study support the concept that the chronic pain itself is the
denominator of cognitive decline and not the associated pathology
giving rise to the chronic pain syndrome.
The direct detrimental effect of pain duration on cognitive
performance in the present study is a new observation, which has
not been reported previously. This negative effect of pain duration
on cognitive performance supports the novel concept of viewing
chronic pain as a disease with neurodegenerative properties. From
Figure 1. Pain duration dependent decrease in cognitive
performance. The figure visualized the pain duration dependent
decrease in cognitive performance. Test scores are depicted (ordinate)
versus duration of pain in years (abscissa). Only the scores on those nine
tests with p#0.05, explaining test scores with predictors ‘pain duration’
are given (see Table 4 lower panel, model 4: ‘pain duration’). The mean
of the scores of the controls (with pain duration zero) on each of the
nine tests was taken as 100%. For those test where an increase in test
score indicated a decrease in performance, the inverse of the raw scores
was taken. The percentage of the test scores of each individual subjects
was calculated. The mean and SE of all these percentages (so of all
subjects on all nine tests) are shown. For each point the number of
subjects is indicated. Remarkable is that the patient that had pain
duration of 11 years had a mean test score on the nine tests
comparable to the controls. This patient was a young patient of only 29
years old.
doi:10.1371/journal.pone.0023363.g001
Cognitive Decline and Chronic Pancreatitis Pain
PLoS ONE | www.plosone.org 7 August 2011 | Volume 6 | Issue 8 | e23363
a therapeutic perspective, the suggestion that neurodegeneration
may be related to chronic pancreatitis pain is extremely relevant.
Typically, chronic pancreatitis patients with pain are treated with
pain medication including opioids over long periods of time, with
limited treatment success and low health-related quality of life,
predominantly as a result of persisting or relapsing pain despite
medication [60]. As a consequence, patients frequently become
unemployed, and may even be deprived of the ability to indulge in
social and sport activities [8]. In this context, earlier and more
effective therapeutic interventions targeting not only the cause of
pain or blocking sensory input, but also specifically addressing the
associated central neuroplasticity might reduce or prevent
neurodegeneration and decline in cognitive performance, thereby
improving the pain outcomes and quality of life in these patients.
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